Author: Editor

Howard S. Hochster, MD of Yale School of Medicine discusses the importance of recommending molecular testing early on to patients with colon cancer. He further explains the significance of HER2 testing in colon cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Howard S. Hochster, MD of Yale School of Medicine discusses the impact of molecular testing and screening on potential clinical trials at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, What is the Optimal Neoadjuvant Strategy in Pancreatic Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Crane, MD of Memorial Sloan-Kettering gives an overview of his presentation, Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy, which was debated with Dr. David Ilson, MD, PhD of Memorial Sloan-Kettering. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Mark A. Schattner, MD of Memorial Sloan-Kettering gives an overview of his presentation, Novel Endoscopic Management of Pancreaticobiliary Cancers, which was presented at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Mark A. Schattner, MD of Memorial Sloan-Kettering explains whether or not there is screen for pancreatic cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

David Ilson, MD, PhD of Memorial Sloan-Kettering discusses questions from the audience that focused on the appropriate chemotherapy for gastric cancer treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

David Ilson, MD, PhD of Memorial Sloan-Kettering explains the impact of radiation therapy on clinical practice. He argues that adding radiation therapy as an obligatory part of adjuvant therapy does not improve overall survival. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

David Ilson, MD, PhD of Memorial Sloan-Kettering gives an overview of his presentation, Debate: Does Radiation Therapy Play a Role in Gastric Cancer Adjuvant Therapy, which was debated with Dr. Christopher Crane, MD of Memorial Sloan-Kettering. He argues that adjuvant radiation therapy adds no benefit to treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses his presentation, Overview of Novel Treatments for HCC in the Era of Hep C Therapies, which was discussed at the 2016 Great Debates and Updates in GI Malignancies in New York, NY

Ghassan Abou-Alfa, MD of Memorial Sloan-Kettering discusses the impact of regorafenib for hepatocellular carcinoma (HCC) treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Jonathan R. Strosberg, MD of Moffitt Cancer Center gives an overview of his presentation, Management of Neuroendocrine Tumors, which was discusses at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Jonathan R. Strosberg, MD of Moffitt Cancer Center discusses the impact of circulating tumor DNA on oncology treatment and management. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Jonathan R. Strosberg, MD of Moffitt Cancer Center gives an overview of his presentation, Is There a Role for Surgical Management of Metastatic Neuroendocrine Cancer, which was debated with Dr. Michael Choti, MD, MBA of UT Southwestern Medical Center. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Yelena Yuriy Janjigian, MD, Memorial Sloan-Kettering gives an overview of her presentation, Molecular Subtyping/Profiling and Update in HER2 Targeted Therapy, which was discussed at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering explains whether or not PDL-1 is a sufficient biomarker in gastric disease. She argues that clinicians should consider a one-stop next generation sequencing. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, New York.

Yelena Yuriy Janjigian, MD of Memorial Sloan-Kettering discusses her presentation, Is Surgery Required After Chemoradiotherapy for Squamous Cancer of the Esophagus, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY. She argues that surgery is a must after chemo-radiation.

http://cancertherapeutics.alliedacademies.com/

Cathy Eng, MD, FACP of MD Anderson Cancer Center discusses her second presentation, which focused on management of anal carcinoma. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Cathy Eng, MD, FACP of MD Anderson Cancer Center gives an overview of her first presentation, Is Circulating Tumor DNA Ready to Guide Adjuvant Therapy in Colon Cancer, which was debated with Dr. Axel Grothey of Mayo Clinic, at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Michael Choti, MD, MBA of UT Southwestern Medical Center gives an overview of his presentation, Is There a Role for Surgical Management of Metastatic Neuroendocrine Cancer, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Michael Choti, MD, MBA of UT Southwestern Medical Center discusses questions from the audience on how to manage early stage neuroendocrine tumors or tumors that are incidentally found. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Zsofia K. Stadler, MD of Memorial Sloan-Kettering explains the role of aspirin therapy in patients with colon cancer and other GI malignancies. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Zsofia K. Stadler, MD of Memorial Sloan-Kettering gives an overview of her second presentation, which focused on the role of genetics in gastrointestinal cancers. She further discusses who should be tested for hereditary syndromes and why. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his second presentation, which focused on optimal adjuvant chemotherapy for resected pancreatic cancer. He further explains the use of gemcitabine and capecitabine for treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains whether or not there is a standard second line treatment for patients with hepatocellular carcinoma (HCC) and who failed first line therapy. He argues that Regorafenib should be used for second line therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic gives an overview of his first presentation, which focused on the availability of new novel agents and therapies for managing patients with metastatic colorectal cancer. He discusses the uses of HER2, BRAF, and Immunotherapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Tanios S. Bekaii-Saab, MD, FACP of Mayo Clinic explains how to integrate HER2, BRAF, and immunotherapy into clinical practice. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his presentation which focused on how to treat left-sided tumors versus right-sided tumors in colorectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Eric Van Cutsem, MD, PhD of University of Leuven gives an overview of his second presentation, which focused on the role of novel agents in colorectal cancer patients. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Eric Van Cutsem, MD, PhD of University of Leuven discusses the impact of left-sided tumors versus right-sided tumors on research in colorectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center discusses the use of technology and its potential breakthroughs for managing patients with colon cancers at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center gives an overview of his presentation, which focused on treatment of left versus right sided colon cancers. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Scott Kopetz, MD, PhD, FACP of MD Anderson Cancer Center gives an overview of the novel therapies that are being used for colon cancer treatment. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Leigh Hallemeier, MD of Mayo Clinic gives an overview of Dr. Julio Garcia-Aguilar’s latest research trial, A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients with Locally Advanced Rectal Cancer Treated with Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management, at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Leigh Hallemeier, MD of Mayo Clinic gives an overview of his presentation, Is Observation Without Surgery Reasonable for Rectal Cancers Achieving a Clinical CR, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Christopher Leigh Hallemeier, MD of Mayo Clinic explains whether or not clinicians can use non-operative management for patients with stage I rectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering gives an overview of new data regarding watch-and-wait approaches in patients with rectal cancer. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering gives an overview of his presentation, Is Observation Without Surgery Reasonable for Rectal Cancers Achieving a Clinical CR, which was debated at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

Julio Garcia-Aguilar, MD, PhD of Memorial Sloan-Kettering discusses patient concerns of risks with delaying surgery months or years after receiving neoadjuvant therapy. This was recorded at the 2017 Great Debates and Updates in GI Malignancies in New York, NY.

http://cancertherapeutics.alliedacademies.com/ Cancer Therapeutics 2017 will be a great platform for research scientists and young researchers to share their current findings in the field of applied sciences.

Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center gives an overview of her presentation, which discusses the survivorship care basics for survivors of colorectal cancer. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center gives an overview of her poster presentation, which was a 12-week home-based walking intervention for patients with advanced pancreatic cancer. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Crystal S. Denlinger, MD, FACP of Fox Chase Cancer Center explains the importance of clinicians speaking about diet, exercise, and healthy living with colorectal cancer survivors. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Becky Lowry, MD of University of Kansas Medical Center gives an overview of her presentation, Survivorship Transitions to Adulthood and Using Telemedicine in Rural Areas, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Becky Lowry, MD of University of Kansas Medical Center discusses the importance of communication between clinicians and survivors during survivorship care. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute gives an overview of her presentation, TP53 Mutation Carriers: Cancer Genetics in Survivorship Care, which was presented at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Junne Kamihara, MD, PhD of Dana-Farber Cancer Institute explains the significance of the shift from single gene testing to multiplex testing.This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania discusses the integration of information on genetic testing into clinical care. She states that with more discussion on genetic testing, more patients will be encouraged to receive testing. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania discusses the challenges that came with incorporating genetic testing into survivorship care. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Angela R. Bradbury, MD of Perelman School of Medicine at the University of Pennsylvania gives an overview of the key points clinicians should know when speaking with patients about genetic testing. This was recorded at ASCO’s 2017 Cancer Survivorship Symposium in San Diego, CA.

Grant Stewart, MBChB, FRCSEd (Urol), PhD, from the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, discusses novel treatments for renal cell carcinoma (RCC) at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the efficacy of combination therapies which can enhance the efficacy of known drugs. Dr Stewart also describes challenges associated with having multiple combination approaches available, and speaks about new approaches to identify good drug combinations.

Gerald Mickisch, MD, from the Bremen Center of Operative Urology, Bremen, Germany, discusses how sequential therapy can be used in the treatment of castration-resistant prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Mickisch explains the efficacy of sequential therapy, and speaks about the order in which treatments are typically given to improve overall survival (OS).

Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses the ARASENS trial for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the three pillars of prostate cancer treatment: androgen deprivation therapy, androgen receptor suppression, and chemotherapy. Prof. Tombal introduces the hypothesis that combining these treatments will improve overall survival (OS), on which the Phase III ARASENS trial (NCT02799602) is based, and outlines the design of this study.

Anne Kiltie, MD, MRCP(UK), FRCR, from the University of Oxford, Oxford, UK, discusses bladder preservation in muscle invasive bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. She describes bladder sparing approaches using a combination of chemotherapy and radiotherapy before carrying out surgery to remove the bladder, and how these vary between different countries. Prof. Kiltie highlights her interest in the treatment of elderly patients, for whom not all therapy options may be available.

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses what uro-oncologists should know about new drugs in 2017 at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Roupret highlights the importance of clinical implications, and explains why clinicians should be informed about what is most important in the management of the disease and treatment side effects.

Morgan Roupret, MD, PhD, from the Pitié-Salpétrière Hospital, Paris, France, discusses optimization of contemporary bladder cancer care at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights that bladder cancer has been treated with the same tools for over 30 years, and speaks about new therapies which are now available. Prof. Roupret also points out why a multidisciplinary team approach is needed for bladder cancer management.

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK, discusses the potential of intraprostatic PRX302 injection for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages of imaging technologies to visualize the tumor, and speaks about how this allows localized treatment to be carried out and what this means for the patient. Prof. Emberton describes different approaches for targeting the tumor, including energy sources and pharmaceutical approaches, and outlines how the effects of the bacterial toxin PRX302 can be limited to the prostate. He speaks…

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Philip D. Bonomi discusses new approaches to the treatment of cachexia. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Nurse Beth Eaby-Sandy discusses how to communicate with families regarding expectations for treatment outcomes. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses the role of zoledronic acid, denosumab, and other strategies in the treatment of bone metastases. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Corey J. Langer discusses the targeting of angiogenesis in non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Ranee Mehra discusses the management of T790-negative EGFR-mutated non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Tracey L. Evans discusses the management of T790-positive EGFR-mutated non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vera Hirsh discusses how, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR-positive non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Barbara A. Burtness discusses current and future strategies for esophageal cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Vassiliki Papadimitrakopoulou discusses the changing face of first- and second-line therapy for squamous cell carcinoma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this discussion, the co-chairs of the European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes 2017 highlight the key points presented during the meeting, with the aim of sharing updates that will help you enhance your clinical practice. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=EMDS © 2017 Imedex, LLC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes the effect and consequences of when ER-p53 tumors attach to mutant p53. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics describes his other study that focuses on the use of tamoxifen therapy for triple negative breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics discusses how to customize therapy based on the stratification of p53. He further explains with the stratification of p53 status, clinicians can now come up with new strategies for treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Gokul Das, PhD of Roswell Park, Department of Pharmacology and Therapeutics gives an overview of his abstract, Novel effect of tamoxifen therapy: disruption of ER-p53 interaction leading to altered gene expression profile in human breast tumors, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center gives an overview of one of her presentations, The Effects of Tumor Microenvironment on Metastasis and Therapy Resistance , which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center discusses the treatment trends for 2017 in oncology at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center gives an overview of one of her presentations, Taming the Tumor Microenvironment in Pancreatic Cancer, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center explains the importance in understanding the language of tumors for cancer research and treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center discusses the research on tumor microenvironment and its impact on cancer research and overall standard of care. She argues the research data helps predict potential tumors and can potentially develop novel pathways and novel treatments to help lower risk in patients. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Valerie M. Weaver, PhD of UCSF Medical Center explains how the genotype of a tumor affects overall tumor behavior and its response to therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses the treatment trends for 2017 which include combination therapy and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses whether or not there is a correlation between biomarkers, specifically PD-L1 and tumor mutation burden, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital discusses the impact of Checkmate-026 on current cancer research, stating the data encourages clinicians to move and assess the biomarkers in all ongoing trials. She also argues that the biomarker can help predict which patients will benefit from early therapeutic treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Solange Peters, MD, PhD of Lausanne University Hospital gives an overview of her presentation, Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis of CheckMate -026, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University discusses the treatment trends for 2017 include immunotherapy and checkpoint inhibitors, but according to him, treatment should focus more on early detection and prevention of cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Athena Matakidou of the Cambridge Cancer Centre discusses Preclinical models of renal cancer at the 12th European International Kidney Cancer Symposium 2017.

Henry Withers of Roswell Park Cancer Institute, Department of Genetics gives an overview of his presentation, Characterization of an off-target RNAi genomic screen hit identifies GPRC6A as a novel suppressor of metastatic chemotaxis and invasiveness, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Henry Withers of Roswell Park Cancer Institute, Department of Genetics discusses how the data can predict which patients are at risk for metastatic disease and his hopes for a potential biomarker that can be used to identify patients with aggressive prostate cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains where to place immunotherapy in overall treatment plans for cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of presentations that were discussed at the AACR 2017 annual meeting. She describes the use of immune checkpoint blocking drugs in four different types of cancers: breast cancer, melanoma, merkel cell carcinoma, and lung cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the use of ipilimumab and nivolumab in advanced melanoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the importance of checkpoint inhibitors, specifically avelumab, in merkel cell cancers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of presentations at the AACR 2017 annual meeting, specifically data results from a clinical trial on triple negative breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Suzanne L. Topalian, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of the AACR presentations, which focused greatly on immunotherapy, biomarkers, and combinations. She further explains the impact of immunotherapy on all types of cancer treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute discusses the use of liquid biopsies of microRNAs as a follow-up method for patients with breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute describes the lack of immunotherapy in treatment for breast cancer, stating the biggest challenge in breast cancer research is figuring out a way to utilize immunotherapy in treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Novel microRNA signature score to predict bone metastasis and prognosis of breast cancer, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kazuaki Takabe, MD, PhD of Roswell Park Cancer Institute discusses whether or not early detection of metastasis can help overall survival in patients with breast cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Brian Rini, MD, Bernard Escudier, MD, James Larkin, MD and Cora N Sternberg, MD outline the challenges and Navigating the RCC Treatment Landscape: Learning from Experience at the 12th European International Kidney Cancer Symposium 2017

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine explains what types of tumors would the new drug be useful for? He argues that the new agent would be useful for all tumors since all tumors rely on a specialized metabolism in order to grow. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine discusses the treatment trends for 2017 which include combining therapy with targeting metabolism. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine explains the importance of targeting metabolism for cancer research. He argues by targeting metabolic pathways, selective tumor cells will be killed, which will enhance not only cancer treatments but immunotherapy as well. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jonathan D. Powell, MD, PhD of Johns Hopkins University, School of Medicine discusses his presentation topic, Immunometabolism in Immunotherapy, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses the treatment trends for 2017 in cancer, which includes immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute explains whether or not AURKA will play a role in melanoma treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute discusses how the data from the AURKA study shows a possibility in combination therapy between MAPK pathway and other inhibitors. He states the future of clinical trials will revolve around this type of combination study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mateusz Opyrchal, MD, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Inhibition of AURKA induces Raf1-independent activation of MAPK pathway in breast cancer cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains the treatment trends for 2017, which include immunotherapy, t-cell therapy, and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains the significance of how tumors evolve from one type of mutation to another. He states that if there is a better understanding of tumor evolution and mutation, clinicians can gain an idea of what needs to be targeted in the future. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute discusses the process of manufacturing products for research at Roswell Park. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute discusses how the persistency of t-cell receptors against cancer can be achieved. He argues with this data, there will be more effective treatments for cancer and lower chances of relapse. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute gives an overview of his presentation, Sustained efficacy of immunotherapy for solid tumors with novel dual CD4/CD8 T cell receptor engineered synergistic combination of hematopoietic stem cells and T cells, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Richard Koya, MD, PhD of Roswell Park Cancer Institute explains how the new data on T-Cell receptors impacts next generation for immunotherapies. He argues how the harnessing of t-cell receptors to recognize cancer cells will benefit future clinical trials. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Evan W. Alley discusses the role of angioinhibition and immunotherapy in the treatment of mesothelioma. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charles B. Simone, II elucidates use of IMRT, proton beam, or SBRT in LA-NSC radiation therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charu Aggarwal discusses attempts to integrate novel targeted agents and immunotherapy into the combined modality paradigm. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Tracey L. Evans discusses whether there are any options beyond chemoteray for non-small cell lung cancer (NSCLC) in the adjuvant setting. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Charles B. Simone, II argues in favor of stereotactic body radiation therapy for early stage non-small cell lung cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Harvey I. Pass argues in favor of surgery for early stage non-small cell lung cancer (NSCLC). Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Anil Vachani discusses when and how to intervene on a growing pulmonary module. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Anil Vachani discusses the impact of the National Lung Screen Trial. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

In this presentation from the 21st Annual Perspectives in Thoracic Oncology, Dr. Shakun M. Malik discusses novel protocol designs in the era of personalized lung cancer therapy. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung © 2017 Imedex, LLC.

Jürgen Gschwend, MD, PhD of the Technical University of Munich School of Medicine and Viktor Grünwald MD, PhD of the Hannover Medical School discuss Treating aRCC in Practice: Current and Future Perspectives at the Kidney Cancer European Symposium 2017.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the treatment trends for 2017. He explains the significance of immunotherapy, but also the potential for intratumoral therapy with combination therapy in future treatments. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of presentations at AACR 2017 and explains the impact of these clinical presentations on future cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey gives an overview of his current research, a phase II study which involved a newly FDA-approved drug, avelumab, in patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains whether or not there is a biomarker to better predict which patients respond to treatment. He states there have been studies for potential biomarkers, but none of the data showed significant responses. He advises all patients should undergo this treatment until clinicians find a biomarker. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey explains the impact of data on future research, stating that avelumab is the only FDA approved drug for Merkel Cell Carcinoma, and with moving forward, future research will involve immunotherapy and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Howard L. Kaufman, MD, FACS of Rutgers Cancer Institute of New Jersey discusses the use of avelumab, a new agent that became available for patients with merkel cell carcinoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the treatment trends in 2017 for patients with MDS and AML, which include introduction of new agents, combination therapy, and immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University explains how the impact of epigenetic therapy could lead to more randomized studies and new standard of care for patients with MDS and AML. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University gives an overview of presentations at AACR 2017, specifically on immunotherapy. He states that in order to make immunotherapy work better for patients, the idea of combining immunotherapy with epigenetic therapy is a possibility moving forward. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University gives an overview of his presentation, Epigenetic Therapy: What Is It, Where Are We, and What Does the Future Hold?, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses questions of concern on the the toxicity of the new epigenetic drugs and speculation on what happens after treatment with these drugs. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jean-Pierre J. Issa, MD of Fox Chase Cancer Center Fels Institute for Cancer Research & Molecular Biology at Temple University discusses the importance of discovering and evaluating new epigenetic drugs for cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University gives an overview of his presentation, Mutational Landscapes of African American Colon Cancers. His presentation was a part of the ‘Minorities in Cancer Research Scientific Symposium: The Role of Diverse Populations in Precision Medicine’ session at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University explains how mutations in genes could potentially be used as biomarkers. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University stresses the importance of finding data from diverse ethnic populations. He argues data from one population might not work or be affective for another. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Kishore Guda, DMV, PhD of Case Western Reserve University discusses the existing social stigmas for ethnic populations in cancer research. He hopes to educate healthcare professionals by removing these misconceptions which will ultimately benefit all diverse groups. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the use of combination therapy to extend duration of anti-androgen therapy response. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new clinical trials that can better assess patient response for treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses his hopes for new targets to treat Androgen Deprivation Therapy (ADT) Resistant Disease. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains whether or not variant cells pre-exist in tumors or if therapy causes these cells to transform. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics explains the transformation of cancers into stem-cell phenotypes, which allows them to adapt to different therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics gives an overview of his abstract, Rb1 suppresses prostate cancer metastasis and lineage plasticity underlying castration resistance, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

David Goodrich, PhD of Roswell Park Cancer Institute, Department of Pharmacology and Therapeutics discusses the treatment trends for prostate cancer in 2017 and gives an overview of an AACR session, which focused on the “Hallmarks of Cancer” and the epigenetic phenomenon that is occurring in cancer research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Toni Choueiri, MD and David McDermott, MD discusses the Immuno-Oncology: Changing the Treatment Landscape in RCC at the 12th European International Kidney Cancer Symposium 2017

Börje Ljungberg from Umeå University Sweden discusses the Development of Guidelines in a Rapidly Changing Treatment Landscape for the John Fitzpatrick Memorial Lecture at the 12th European International Kidney Cancer Symposium 2017.

Bernard Escudier of the Gustave Roussy discusses Brain mets under I.O. at the 12th European International Kidney Cancer Symposium 2017

Guillermo de Velasco MD, PhD University Hospital 12 de Octubre discusses SBRT for lung metastases: Case report at the 12th European International Kidney Cancer Symposium 2017

Manuela Schmidinger of the Medical University of Vienna discusses the Solitary Bone Mets Spinal at the 12th European International Kidney Cancer Symposium 2017

Camillo Porta, MD of the I.R.C.C.S. San Matteo University Hospital Foundation answers the question How should the next generation of trials address the question of the sequence? at the 12th European International Kidney Cancer Symposium 2017

Gabriel Malouf, MD, PhD of Pitié-Salpêtrière Hospital Defines Optimal 2nd Line Treatment and Sequence: Biomarker at the 12th European International Kidney Cancer Symposium 2017

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Eric P. Winer looks back at the advances made in the treatment of breast cancer in the last few decades in an effort to elucidate how to best move forward in 2017. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Dawn L. Hershman discusses the latest insights in breast cancer prevention, survivorship, and health care delivery. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Constantine Godellas discusses the latest advances in local-regional approaches for the treatment of breast cancer. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

David McDermott, MD of the Dana-Farber/Harvard Cancer Center outlines and Defines Optimal 2nd Line Treatment and Sequence: Subgroup Analysis from Pivotal Studies and Real World Data at the  12th European International Kidney Cancer Symposium 2017

John B.A.G. Haanen MD PhD of the The Netherlands Cancer Institute discusses Anti-PD1 PDL1 + anti-VEGFR in Kidney Cancer at the  12th European International Kidney Cancer Symposium 2017

Toni K. Choueiri, MD of the Dana-Farber Cancer Institute discusses the changes in first line kidney cancer treatment for 2018 at the  12th European International Kidney Cancer Symposium 2017

Thomas Powles MD of Barts Cancer Institute discusses the Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients at the  12th European International Kidney Cancer Symposium 2017

Hans Hammers, MD, PhD, UT Southwestern discusses the Dual Immune Checkpoint Blockade at the  12th European International Kidney Cancer Symposium 2017

Alain Ravaud, MD.PhD takes the pro side of the debate entitled Adjuvant Therapy Ready For Prime Time In Kidney Cancer at the  12th European International Kidney Cancer Symposium

Tanja de Gruijl, VU University Medical Center discusses Harnessing the sentinel lymph node Translational perspective: LN as the first priming site of the immune system at the  12th European International Kidney Cancer Symposium 2017

Prof. Dr. med. Viktor Grünwald of the Medical School Hannover outlines the Oncologists perspective LN as metastatic spread at the  12th European International Kidney Cancer Symposium 2017

Jose A. Karam, MD, FACS, Associate Professor Department of Urology MD Anderson Cancer Center discusses Surgeons Perspective: LN as a Draining Pattern from the 12th European International Kidney Cancer Symposium 2017

Aung Naing of MD Anderson Cancer Center discusses PEGylated Human IL-10 AM0010 in Combination with Nivolumab in Renal Cell Cancer at the  12th European International Kidney Cancer Symposium 2017

Cynthia Macahilig of the University of Manchester discusses Health-Related Quality of Life, Treatment Satisfaction, and Work Productivity for Patients With Advanced Renal Cell Carcinoma in a Chart Review Across Six Countries  12th European International Kidney Cancer Symposium 2017

Hans J. Hammers, MD of the University of Texas Southwestern Medical Center discusses Updated Results From a Phase I Study of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study from the  12th European International Kidney Cancer Symposium 2017

Krzysztof Krawczyk of the Department of Translational Medicine, Center for Molecular Pathology Lund University, Malmö, Sweden discusses the papillary renal cell carcinoma-derived chemerin, IL-8 and CXCL16 attract and differentiate monocytes at the  12th European International Kidney Cancer Symposium 2017

Saeed Dabestani MD PhD student Lund University, Sweden discusses the Non-metastatic renal cell carcinoma follow-up, recurrences and outcomes a RECUR database analysis at the  12th European International Kidney Cancer Symposium 2017

Axel Bex, MD, PhD, of The Netherlands Cancer Institute in Amsterdam discusses the Challenges in Surgical Trials for Kidney Cancer at the  12th European International Kidney Cancer Symposium

In this activity, meeting co-chair Dr. John P. Leonard provides the key take-home messages from the leukemia, myeloid disorders, and benign hematology sessions at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7254 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Kathy S. Albain discusses updates in adjuvant and neoadjuvant therapy for the treatment of breast cancer, and elaborates on the latest data on predictors of benefit. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Debu Tripathy discusses novel therapeutics for the treatment of breast cancer, with a focus on HER2+ and triple negative disease. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this presentation from the 14th Annual Best of San Antonio – Breast Cancer: Bench to Bedside, Dr. Hope S. Rugo discusses novel therapeutics for the treatment of breast cancer, with a focus on CDK inhibitors, immunotherapy, and the role of tumor infiltrating lymphocytes. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7244 © 2017 Imedex, LLC.

In this activity, meeting co-chair Dr. David P. Steensma provides the key take-home messages from the leukemia, myeloid disorders, and benign hematology sessions at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for this activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7253 © 2017 Imedex, LLC.

In this activity, meeting co-chair Dr. Robert Z. Orlowski provides the key take-home messages from the plasma cell disorder session at the 2017 Great Debates & Updates in Hematologic Malignancies, held April 7-8, 2017. Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=7252 © 2017 Imedex, LLC.

Dr. Arnaud Mejean, MD presents the challenges in CARMENA from the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany

Dr. Thomas Powles, MD presents the Challenges in Neoadjuvant Biomarker Trials at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany.

Axel Bex, MD presents Challenges In Surtime at the 2017 12th Annual European Kidney Cancer Symposium, Munich Germany       kidney cancer, challenges in surtime  

Dr. Cora Sternberg, MD presents the P.H.M. deMulder Lecture entitled From cytokines to targeted therapies to immunotherapy30 years of progress in advanced RCC at the 12th Annual 2017 Kidney Cancer European Meeting in Munich, Germany.

Bernard J. Escudier, MD introduces Dr. Cora Sternberg, MD before the P.J.M. dMulder Lecture at the 12th Annual European Kidney Cancer Meeting 2017

Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the treatment trends for lymphoma in 2017, which include targeted therapy, chemotherapy, and combination therapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an overview of his presentation, CHRONOS-1, which shows the use of copanlisib in B-Cell Lymphoma patients. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC. CORRECTION: Follicular Lymphoma subset ORR was 59.7% MZL group was 69.6%

Martin Dreyling, MD of University of Munich Hospital in Grosshadern gives an update on immunotherapy, which was a hot topic of AACR 2017. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Martin Dreyling, MD of University of Munich Hospital in Grosshadern explains the difference between copanlisib and other PI3K inhibitors, specifically Idelalisib He argues that copanlisib seems to be better tolerated in patients than Idelalisib. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Martin Dreyling, MD of University of Munich Hospital in Grosshadern discusses the impact of his clinical trial, CHRONOS-1, on current and future cancer research. He states that the compounds of drugs are affective in any stage of disease and that the data continues to show the important roles of PI3K Inhibitors. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the treatment trends in 2017 for his field, neuro-oncology, which include more use of checkpoint inhibitors and combination therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of the AACR presentations, which show more data and focus on exosomes and blood biopsies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how intracellular targets are detected onto the cell surface. He states that this target is a protein that usually does not belong on the cell surface, but has been detected through an antibody. The uncertainty of how this target moved is part of exciting new research in glioma biology. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute explains how the clinical data will help better characterize which patients respond to immunotherapy. Specifically, this data would tell clinicians which patients respond to the survivin vaccine. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute discusses the impact his clinical trial has on clinicians and future research. He states that if they continue to build more data, then the study could potentionally predict when a patient may recur. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Michael Ciesielski, PhD of Roswell Park Cancer Institute gives an overview of his abstract, Circulating CD9-GFAP-survivin exosomes during active specific immunotherapy, a potential biomarker for glioma, which was presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives her input on when patients should stop treatment. She states that if the patient shows responsive to treatment, then she would feel comfortable allowing the patient to stop early. She also explains whether or not all patients should have PD-L1 staining. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains how this clinical trial now allows clinicians and other healthcare professionals to quote five-year data to patients with non-small cell lung cancer. She argues the impact of this data will give hope to lung cancer patients of their options. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center discusses the treatment trends for 2017 in thoracic oncology. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of her presentation which discussed a five-year follow-up of Lung Cancer patients, who were treated with Nivolumab. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center explains the impact of her clinical trial on current clinicians and future research. She argues how this trial is the first trial to show a five-year survival rate for non-small cell lung cancer. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Julie Brahmer, MD of Johns Hopkins Kimmel Comprehensive Cancer Center gives an overview of some of the presentations that were discussed at AACR 2017. She states that these presentations range from Merkel Cell Carcinoma to Immunotherapy for Breast Cancer and Melanoma. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, explains that there is a big debate on whether robots should be used for surgical procedures at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Albers highlights that the complications which are seen are different compared to open surgery, however there are great visibility advantages of robot-assisted surgery. Prof. Albers points out that there is a lack of data comparing in detail robotic and open surgery. Aspects which need to be considered when comparing robotic and open surgery include familiar parameters, such as rate of positive margins, time…

Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, discusses how checkpoint inhibitors can be used earlier in bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that the current focus of immune checkpoint inhibitors in bladder cancer is in the advanced or metastatic stage. However, according to Prof. Powles, the bigger picture involves bringing these drugs into earlier disease stages. He speaks about checkpoint inhibitors which are being trialed in an adjuvant setting (CheckMate 274, NCT02632409; IMvigor010, NCT02450331) and neoadjuvant setting (NCT02451423). Prof. Powles concludes that the story of…

Thomas Powles, MBBS, MRCP, MD, from the Barts Cancer Institute, London, UK, gives an overview of the use of checkpoint inhibitors in metastatic urothelial bladder cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that the differences seen clinically with immune checkpoint inhibitor treatment, and speaks about recent clinical trial results. According to Prof. Powles, one of the next key questions which needs to be addressed is whether frontline randomized Phase III studies show improved outcomes with immunotherapy compared to chemotherapy in bladder cancer. Whether biomarkers will be important for this also needs to…

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the current landscape and future direction of systemic therapy for renal cell carcinoma (RCC) at the European Association of Urology (EAU) conference 2017 in London, UK. She highlights that impressive developments have been seen in metastatic kidney cancer. She describes results from a randomized Phase II study using a combination of lenvatinib and everolimus (NCT01136733), as well as the CheckMate 025 Phase III randomized trial (NCT01668784) and Phase III METEOR trial (NCT01865747) comparing everolimus with cabozantini. According to Prof. Osanto, recent trials have revolutionized the treatment of…

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical implications of circulating tumor cell (CTC) analysis in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. She argues that for patients with localized prostate cancer, there is currently no evidence that circulating tumor cells can be used in a clinical setting to monitor disease or treatment outcomes. In contrast, in patients with a higher tumor load, such as those with castration-resistant prostate cancer (CRPC) who need to undergo system treatment or in whom we know that treatment resistance has…

Susanne Osanto, MD, PhD, from the Leiden University Medical Center, Leiden, Netherlands, discusses the clinical utility of circulating tumor cells (CTCs) at the European Association of Urology (EAU) conference 2017 in London, UK. She argues that this is a very powerful approach, which allows patients with metastatic disease to be tested for disease presence and the number of circulating cells, as well as the characteristics of the tumor cells. Prof. Osanto explains how circulating tumor cells can be molecularly profiled at a single-cell level.

Rong Na, MD, from the Huashan Hospital, Fudan University, Shanghai, China discusses germline mutations in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He introduces a study whose aim was to evaluate the association between germline mutations in DNA repair genes and the risk of prostate cancer, which evaluated the rate of carriers in lethal and indolent prostate cancer patients, as well as survival time. Dr Rong Na also discusses the next steps in this study.

Peter Albers, MD, from the Heinrich-Heine-University Düsseldorf, Germany, discusses which factors are important to consider in surgical robots at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the advantages presented by robot-assisted surgery and points out new imaging technologies which are only possible in laparoscopic or robot-assisted surgery. Prof. Albers argues that the future of surgery will be in a minimally invasive approach and that technical improvements are necessary to maximize the advantages of robotic surgery.

Jame Abraham, MD of Cleveland Clinic discusses his hopes for NSABP-FB10 becoming a Phase II and Phase III trial for patients with breast cancer. He also discusses how to manage the diarrhea and nausea in patients who underwent this study. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic gives an overview of his abstract, NSABP FB-10: Phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DMI) with neratinib (N) in women with metastatic HER2+ breast cancer, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic discusses the key finding from his study shows the impact of neratinib for breast cancer treatment. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic states that although breast cancer treatment has yet to include immunotherapy, it is still dominating the field of cancer as a whole. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Jame Abraham, MD of Cleveland Clinic discusses the treatment trends for breast cancer, which include PARP inhibitors, CDK 4/6 Inhibitors, and Immunotherapy. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic explains the determinants of what allows tumor samples to be released into the blood stream. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic explains the need for a genomic encyclopedia for radiation oncology. He argues that a genomic encyclopedia could help when deciding treatment if they already know which patients respond to certain therapies. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses his speciality, radiation oncology, and the treatment trends he sees for 2017. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses Joe Biden’s address to AACR and the importance of receiving funding from these types of organizations for cancer genomics and research. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic discusses the impact of his panel discussion and his hopes towards the ability of extracting genomic information from these tumor samples, whether it’s through tumor sampling or liquid sampling. This was recorded at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

Mohamed Abazeed, MD, PhD of Cleveland Clinic gives an overview of his panel discussion, Radiation Science and Medicine Working Group Town Hall Meeting and Networking Reception, which was discussed at the American Association for Cancer Research (AACR) 2017 Annual Meeting in Washington, DC.

In this roundtable discussion, Drs. Gerald Prager, Tanios Bekaii-Saab, and Eric Van Cutsem examine the safety and efficacy profiles of the available agents for patients who have failed first- and second-line therapy, provide insight into how to manage adverse effects, and elucidate how best to incorporate said agents in the appropriate sequence, either in combination or alone, when they are available. Earn CME Credit for this activity: http://bit.ly/2lzM53l

In this Key Insights activity, Dr. Scott Kopetz and conference chair David H. Ilson discuss the key non-colorectal cancer-related take-home messages from the 2017 Great Debates and Updates in Gastrointestinal Malignancies conference held March 24-25, 2017 in New York. Earn CME Credit for this activity: http://bit.ly/2oeonuL

In this Key Insights activity, Dr. Scott Kopetz and conference chair Axel Grothey discuss the key colorectal cancer-related take-home messages from the 2017 Great Debates and Updates in Gastrointestinal Malignancies conference held March 24-25, 2017 in New York. Earn CME Credit for this activity: http://bit.ly/2oeokiz

Recorded on site during the 18th European CongressL Perspectives in Lung Cancer, this activity features conference chairs Giorgio V. Scagliotti, MD, PhD and Luis Paz-Ares, MD, PhD discussing the key take-home points from the meeting. Earn CME Credit for this activity: http://bit.ly/2oyBiZv

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of MRI in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. Prof. Emberton explains that MRI allows the cancer to be identified, described, characterized and biopsied better, and will hopefully in future allow it to be treated better. He describes the PROMIS study (NCT01292291), and highlights that at EAU 2017, the ramifications of these data are just being explored. He concludes that MRI in prostate cancer offers more opportunity, fewer and better biopsies, better risk stratification,…

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the joint meeting of the EAU and Japanese Urological Association at the European Association of Urology (EAU) conference 2017 in London, UK. European and Japanes uro-oncologists discussed the best second-line treatment in advance metastatic renal cell carcinoma (RCC).

Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the limitations of magnetic resonance imaging (MRI) in prostate cancer diagnosis at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that MRI can be used as a triage test in patients with suspicion of prostate cancer who have not yet had a diagnostic workup for prostate cancer. Some studies have described that if an MRI is negative in this case, there is no need to worry about the presence of significant cancer, while others have observed that significant cancer can be missed when using this…

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the implications of earlier immune-oncology treatments for multidisciplinary teams at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Bellmunt highlights the new results on immune-oncological agents presented at this conference, and that the treatment of urological cancers requires a multidisciplinary team approach.He says it is crucial that the community treating genitourinary patients is aware of the treatment advances, and how to manage these in the setting of earlier treatments.

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the currently available androgen deprivation therapies (ADT) at the European Association of Urology (EAU) conference 2017 in London, UK. He argues that an important factor is which ADT is used, as they have different mechanisms of action and response times.

Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses results from the ProtecT trial in prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. This Phase III prospective randomized clinical trial evaluated the efficacy of different treatment modalities in low and intermediate risk prostate cancer. He outlines the data presented at EAU 2017, which focused on histological features of tissue from patients in the ProtecT trial. Discriminating between patients that progressed and those that did not, pathophysiology was retrospectively assessed in biopsy tissue, as well as the entire prostate if surgery was carried out. He explains…

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, speaks about highlights from the session on advanced prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He says that there was a lot of discussion about advanced prostate cancer, such as what to do with lymph node recurrence after prostatectomy if cancer is found in a small number of lymph nodes in the pelvis after a period of remission. A subsequent presentation covered the complications of this procedure. The session also covered systemic therapy in metastatic castration-resistant prostate cancer, and Prof. Merseburger highlights a study…

Maurizio Brausi, MD, from the AUSL Modena, B. Ramazzini Hospital, Modena, Italy, discusses clinical trials of robotic surgery in radical cystectomy at the European Association of Urology (EAU) conference 2017 in London, UK. According to Prof. Brausi, the most important randomized trial in robotic surgery for radical cystectomy is a Phase III study carried out at the Memorial Sloan Kettering Cancer Center in New York, NY (NCT01076387). Prof. Brausi summarizes the results of the trial, and concludes that robotic surgery for muscle invasive bladder cancer shows promise but is not yet the standard.

Mark Emberton, MD, FRCS Urol, from University College London Hospitals NHS Foundation Trust, London, UK discusses the value of videos to communicate science at the European Association of Urology (EAU) conference 2017 in London, UK.

Jochen Walz, MD, from the Paoli-Calmettes Institute, Marseille, France, discusses the advantages of using imaging information for prostate cancer diagnosis and management at the European Association of Urology (EAU) conference 2017 in London, UK. Dr Walz explains that prostate cancer, according to EAU guidelines, is currently diagnosed by randomized biopsy without using imaging information to target the tumor. Several technologies are available to promote the use of imaging information in prostate cancer diagnosis. Reliable imaging will allow decisions to be made on whether a cancer needs to be treated or followed by active surveillance. He concludes that the use of…

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, gives an overview of checkpoint inhibitors for urothelial carcinoma treatment at the European Association of Urology conference 2017 in London, UK. Immunotherapy has been developed in patients with advanced disease failing first- or second-line treatment. Dr Bellmunt explains that based on the results seen, immunotherapy is now being moved to earlier phases of the disease and as a first-line treatment in patients with metastatic disease, patients ineligible for chemotherapy, or in an adjuvant or neoadjucant setting. Looking forward, Dr Bellmunt explains that biomarkers are being identified which will allow…

In this presentation from Lymphoma & Myeloma 2016, Dr. Kelly M. Trevino discusses strategies to focus on quality of life when choosing a lymphoma therapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson argues for the use of novel agents for a 60 year patient with follicular lymphoma who has relapsed less than two years after receiving upfront R-CHOP therapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. David G. Maloney argues for stem cell transplant for a 60 year patient with follicular lymphoma who has relapsed less than two years after receiving upfront R-CHOP therapy. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Jeremy S. Abramson discusses the latest novel agents for the treatment of follicular lymphoma. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Jia Ruan discusses the most promising new approaches and agents for the treatment of T cell lymphoma. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Kieron Dunleavy discusses the latest developments in the upfront and relapsed treatment settings of primary CNS lymphoma. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. Sonali M. Smith discusses whether or not one should utilize cell of origin and “double protein” expression in the treatment of diffuse large b-cell lymphoma (DLBCL). Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

In this presentation from Lymphoma & Myeloma 2016, Dr. George P. Canellos discusses the past, present, and future of Hodgkin disease. Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

How should we approach the adolescent/young adult Hodgkin lymphoma patient? Click to Earn CME Credit: http://bit.ly/2mFKBrY © 2016 Imedex, LLC.

Christian Stief, MD, from Ludwig-Maximilians-University, Munich, Germany discusses developments in prostate cancer presented at a video session at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that prostate fusion biopsy, which combines MRI and ultrasound imaging, is becoming more readily available, and comparable to biopsy carried out in the MRI apparatus. Prof. Stief points out that fusion biopsy is cost effective and much easier for patients to endure, while also giving precise information on the tumor itself and the extent of the tumor. He also speaks about cryotherapy, where a specific spot undergoes cryotherapy right…

Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the use of social media in uro-oncology at the European Association of Urology (EAU) conference 2017 in London, UK. He explains that using Twitter for just 15 minutes a week allows him to keep up to date with the latest news from conferences. Prof. Merseburger believes that Twitter is a good resource; it does not replace face to face meetings or conferences, but if someone is not able to go to a conference, Twitter allows them to get fast and immediate information on what is happening in their peer group.

Drs. Jared Weiss, Assistant Professor, Clinical Research Hematology/Oncology, University of North Carolina School of Medicine, and Josh Bauml, Assistant Professor of Medicine, Hospital of the University of Pennsylvania, join GRACE to discuss updates relating to pembrolizumab, nivolumab and PD-L1 markers for head and neck cancers.

From our MPN Ask the Expert series, Patient Power viewer, Maryse, asks a question about the MPL mutation and if there are targeted treatments being developed for this mutation. Dr. Prithviraj Bose from The University of Texas MD Anderson Cancer Center responds by explaining the MPL mutations as it relates to others like JAK2 and CALR and goes on to discuss treatments that are meant to target the JAK-STAT pathway. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Joaquim Bellmunt, MD, PhD, from the Dana-Farber Cancer Institute, Boston, MA, summarizes the aims and results of the KEYNOTE-045 (NCT02256436) trial of pembrolizumab as a second-line agent in the treatment of urothelial carcinoma at the European Association of Urology conference 2017 in London, UK. He explains that this Phase III randomized trial was carried out in patients failing first-line platinum-base chemotherapy, or second- or third-line chemotherapy in some cases. Patients received pembrolizumab every three weeks, or standard of care chemotherapy (paclitaxel, docetaxel, or vinflunine). Dr Bellmunt highlights that this is the first trial showing an advantage of immunotherapy over chemotherapy…

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains which patients should get endocrine therapy and genomic profiling in breast cancer. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center explains the use of genomic profiling for prognoses in breast cancer, which shows the chances of relapse and a prediction for endocrine therapy or chemotherapy. He states that with genomic profiling, oncologists can tailor their treatments based on these results. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses the treatment trends in 2017 for estrogen receptor positive breast cancer, which include the use of CDK46 inhibitors. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.

Lee S. Schwartzberg, MD of University of Tennessee Health Science Center discusses current clinical trials and genomic profiling in breast cancer research. This was recorded at the 2017 National Comprehensive Cancer Network (NCCN) Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care in Orlando, Florida.